
|Videos|June 14, 2018
AR-V7 Key in Tx of mCRPC
Author(s)Andrew Armstrong, MD
In this video, Dr. Andrew Armstrong explains why AR-V7–positive men rarely benefit from abiraterone or enzalutamide, and advises on AR-V7 testing as a clinical tool.
Advertisement
In this video, Dr. Andrew Armstrong explains why AR-V7–positive men rarely benefit from abiraterone or enzalutamide, and advises on AR-V7 testing as a clinical tool.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
3
Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC
4
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
5




































